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We report on the evaluation and management of a 47-year-old white male found to have primary carcinoid tumor of the ileal
segment of his diverting ileovesicostomy thirty-ﬁve months after initial creation. Subsequent to presentation with intermittent
gross hematuria, CT urogram highlights an 8mm enhancing lesion near the enterovesical junction of urinary diversion. Oﬃce
cystoscopy conﬁrms presence of a lesion that was later endoscopically resected and found to be a well-diﬀerentiated carcinoid
tumor. Evaluation with serum markers, direct visualization utilizing endoscopy, and imaging was without ﬁnding of alternate
primary or metastatic lesions. The patient ultimately had the proximal ileal portion of his ileovesicostomy excised and the distal
portion converted into an ileal conduit. After brieﬂy discussing the carcinoid tumor and the carcinoid syndrome it may cause, we
review the literature on the incidence of carcinoid tumors in a population requiring the use of intestine in the urinary tract.
1.Introduction
Carcinoid tumors were ﬁrst described over a century ago
by Lubarsch with the term karzinoide used by Oberndorfer
in 1907 to describe tumors that were slower growing than
typical adenocarcinomas [1]. Carcinoid is a slow-growing
tumor originating from cells of the neuroendocrine system.
Carcinoid is most often found in the gastrointestinal system,
namely, in the ileum and the appendix. However, carcinoid
also has a high incidence in the lung. The incidence of
carcinoid tumors ranges from 2.5 to 5 per 100,000 [2].
Carcinoid has the potential to become malignant and cause
the carcinoid syndrome, resulting from excessive activation
ofbiogenicamines,bradykinins,andtachykininsthroughout
systemic circulation. The carcinoid syndrome causes a
plethora of symptoms including watery diarrhea, wheezing,
abdominal pain, and heart failure. Carcinoid of the small
bowel may account for 90% of the incidence of carcinoid
syndrome [3].
2.CaseReport
A 47-year-old man, with paraplegia related to a T7 spinal
cord injury suﬀered at the time of a motor vehicle collision
nearly 30 years prior, originally presented carrying the
diagnosis of neurogenic bladder that had been managed
by indwelling foley catheter. At that time, physical exam
demonstrated the manifestations of urethral erosion which
would later be complicated by development of a necrotic
phallus and eventual loss of this appendage by means of
partial penectomy. As a means of urinary diversion, he
underwent creation of an ileovesicostomy that was later
revised due to redundancy of the eﬀerent limb. At the time of
revision, a concurrent bladder neck ligation was performed
due to persistent urinary incontinence per urethra. Thirty-
ﬁve-month status after original diverting procedure, a CT
urogram was obtained to evaluate complaint of intermittent
gross hematuria. This study demonstrated an enhancing
8mmmassneartheenterovesicalanastamosisoftheileovesi-
costomy (Figure 1). Oﬃce cystoscopy conﬁrmed the ﬁnding,
andsubsequentcold-cupbiopsywasobtainedusingaﬂexible
cystoscopy in the operative suite. An acquired pathologic
specimen was consistent with well-diﬀerentiated neuroen-
docrine carcinoma, consistent with carcinoid (Figure 2). The
lesion was conﬁned to the ileal mucosa. The four biopsy sites
measured approximately 2mm each in greatest diameter.
Special histologic markers for carcinoid, including synap-
tophysin, chromogranin, and pankeratin, stained positive.2 Case Reports in Urology
Table 1: Summary showing the initial presentation, diagnostic studies, and treatment of carcinoid in urinary diversions.
Author Duration of urinary
diversion Reason for diversion Symptoms Diagnostic studies Treatment
Frese et al. ∼9 years Invasive TCC of the
bladder
None (found during
surveillance
cystoscopy)
Cystoscopy
Urethrectomy, removal
of neobladder, creation
of ileal conduit
K e r f o o te ta l . 9y e a r s
Invasive
adenocarcinoma of
the bladder
Intermittent bilateral
ﬂank pain
Intravenous
pyelogram (IVP)
Excision of obstruction
with end-to-end
reanastomosis
Klink et al. 28 years Pelvic exenteration
for cervical cancer Gross hematuria
CT abdomen/pelvis,
IVP, cystoscopy, urine
cytology
Resection of the ileal
conduit and creation of
an e wo n e
Kochevar 12 years
Recurrent
pyelonephritis
secondary to ureteral
stenosis
Abdominal Pain,
recurrent UTIs
Ultrasonography, IVP,
cystoscopy
Excision of obstruction
with end-to-end
reanastomosis
Figure 1: An arterial phase view of the carcinoid tumor seen on
CT urogram. The tumor is located at the anterior portion of the
cystoplasty along the bladder-ileum border (arrows pointing to area
of concern for tumor).
An ensuing octreotide scan, esophagogastroduodenoscopy,
and colonoscopy were all without evidence of alternate
primary or metastatic site. Given the paucity of literature
regardingsuchalesion,noclearlydeﬁnedalgorithmoutlined
on how to proceed. Thus, repeat cold-cup biopsy was
performed at site of previous excision. Pathologic tissue
was without evidence of malignancy. Despite negative repeat
biopsy, the patient elected to proceed with excision of the
proximalaspectofhisileovesicostomywiththedistalportion
converted into an ileal conduit.
3. Discussion
According to the 2010 National Comprehensive Cancer
Network (NCCN) guidelines for neuroendocrine tumors,
triple phase CAT scan or MRI of the abdomen or pelvis is
the ﬁrst-line imaging modality for evaluation of a carcinoid
tumor [4]. Octreotide scan, colonoscopy, and small bowel
imaging may be considered as appropriate.
Treatment of a localized carcinoid in the ileum should
involve resection of the aﬀected segment of ileum with
Figure 2: A high-powered histologic view of the carcinoid tumor.
This tumor demonstrates the carcinoid tumor cell’s characteristic
ovoid nuclei with scant cytoplasm along with a ﬁbrovascular
stroma.
associated mesentery. For patients with the carcinoid syn-
drome, octreotide is considered ﬁrst line therapy. Depending
on the organ system, therapy for metastatic carcinoid may
diﬀer. Treatment may include chemotherapy and, if feasible,
resection of metastases. Precise treatment for each organ
system aﬀected by carcinoid syndrome is beyond the scope
of this review.
To our knowledge, this is the ﬁrst case of a carcinoid
tumor within an ileovesicostomy described in the urologic
literature. A MEDLINE review of “carcinoid tumors” and
“urinary diversion” reveals ﬁve results, a testament to the
rarity of these tumors and among the reports of carcinoid
in intestine used in other forms of the urinary tract; there
are three cases seen in an ileal conduit [5–7]a n do n ec a s eo f
carcinoid in an ileal neobladder [8]. The ﬁfth case included
in the MEDLINE review is an appendiceal carcinoid tumor
with metastasis to the small and large bowels and omentum
causing urinary obstruction and the carcinoid syndrome.
The authors of that paper created a cutaneous ureterostomy
to relieve the obstruction [9].
Among the cases involving intestine used in urinary
diversion, Frese et al. reported on the case of carcinoidCase Reports in Urology 3
in an ileal neobladder [8]. Their patient is a 64-year-
old man who underwent radical cystectomy and creation
of the neobladder for invasive transitional cell carcinoma.
The patient’s lesion was discovered endoscopically upon
routine surveillance cystoscopy. Klink et al. presented the
case of a 74-year-old woman with gross hematuria from her
ileal conduit and resulting tumor that was carcinoid. This
patient’s conduit was ultimately excised with the creation of
an e wc o n d u i t[ 5]. Kerfoot et al. report a 61-year-old woman
with carcinoid of an ileal conduit that leads to conduit
stenosis and hydronephrosis [6]. Finally, Kochevar presents
the case of a 55-year-old woman with abdominal pain,
urinary obstruction, and recurrent urinary tract infections.
Their patient had a stenosis of her ileal conduit as a result
of carcinoid [7]. The area of concern in the conduit was
resected, and an end-to-end anastomosis was created. In
all four cases the carcinoid syndrome was not present as
summarized in Table 1.
We report a case of a unique occurrence, carcinoid in
intestine used in the urinary tract. More speciﬁcally,we show
the ﬁrst case reported in the urologic literature of a carcinoid
tumor in a segment of ileum used in a bladder augment.
Due to the low incidence of this unique type of tumor in an
urologic patient, deﬁnitive treatment algorithms are absent.
Interestingly, this patient had a CT scan prior to his initial
surgery of bladder augment with ileovesicostomy that was
freeoftumorburden.Thequestionofwhethertheuseofthis
segment of ileum in bladder augmentation contributed to
the patient’s carcinoid tumor is an interesting one. However,
due to the low incidence of this tumor type, it is not possible
to draw conclusions about the cause of the carcinoid tumor
at this time.
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